Chronic hepatitis C and hematological malignancies

VIRAL INFECTIONS IN ONCOHEMATOLOGY , , ,

A.O. Bueverov1 and P.O. Bogomolov2

1 I.M. Sechenov First Moscow State Medical University, RF MH, Moscow, Russian Federation

2 M.F. Vladimirsky Moscow Regional Research-and-Clinical Institute, Moscow, Russian Federation

ABSTRACT

Reactivation of chronic HCV-infection in cases of drug immunosuppression occurs relatively infrequently and rarely manifests itself as clinically significant liver injury. Certain alertness is required when such patients are treated with monoclonal antibodies in combination with glucocorticoids. Due to the extremely limited potentials of etiotropic therapies for HCV-infection in patients receiving immunosuppressive drugs for hematological malignancies, it is reasonable to follow the approaches similar to those in drug-induced hepatitis.

Keywords: chronic hepatitis C, immunosuppressive drugs, viral reactivation, drug-induced liver injury.

Read in PDF (RUS)pdficon

REFERENCES

  1. Буеверов А.О. Хронические заболевания печени. Краткое руковод- ство для практикующих врачей. М.: МИА, 2013.  [Buyeverov A.O. Khronicheskiye zabolevaniya pecheni. Kratkoye rukovodstvo dlya praktikuyushchikh vrachey (Chronic liver diseases. Concise manual for medical practitioners). M.: MIA, 2013.]
  2. Рекомендации по ведению взрослых больных гепатитом С. Клин. перспект. гастроэнтерол. гепатол. 2013; 2: 3–32. [Recommendations on management of adult patients with hepatitis C. Klin. perspekt. gastroenterol. gepatol. 2013; 2: 3–32. (In Russ.)].
  3. Maasoumy B., Wedemeyer H. Natural history of acute and chronic hepatitis C. Best Pract. Res. Clin. Gastroenterol. 2012; 26: 401–12.
  4. Zeisel M.B., Fofana I., Fafi-Kremer S., Baumert T.F. Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies. J. Hepatol. 2011; 54: 566–76.
  5. Liang T.J., Ghany M.G. Current and future therapies for hepatitis C virus infection. N. Engl. J. Med. 2013; 368: 1907–17.
  6. De Clercq E. Antivirals: past, present and future. Biochem. Pharmacol. 2013; 85: 727–44.
  7. Chevaliez S., Rodriguez C., Pawlotsky J.M. New virologic tools for management of chronic hepatitis B and C. Gastroenterology 2012; 142: 1303–13.
  8. Богомолов П.О., Буеверов А.О., Мациевич М.В. и др. Возможности повы- шения эффективности противовирусной терапии больных хроническим гепатитом С, инфицированных 3-м генотипом вируса. Инфек. бол. 2012; 2: 8–14. [Bogomolov P.O., Buyeverov A.O., Matsiyevich M.V. et al. Potentials of enhanced efficacy of antiviral therapy in patients with chronic hepatitis C, infected with 3rd virus genotype. Infek. bol. 2012; 2: 8–14. (In Russ.)].
  9. Monti G., Pioltelli P., Saccardo F. et al. Incidence and characteristics of non-Hodgkin lymphomas in a multicenter case file of patients with hepatitis C virusrelated symptomatic mixed cryoglobulinemias. Arch. Int. Med. 2005; 165: 101–5.
  10. de Vita S., Quartuccio L., Isola M. et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthr. Rheum. 2012; 64: 843–53.
  11. Bonilla-Abadia F., Echeverri A.F., Izquierdo J.H. et al. Efficacy and safety of rituximab in the treatment of vasculitic leg ulcers associated with hepatitis C virus infection. Case Rep. Rheumatol. 2012; 20: 923–37.
  12. Firpi R.J., Nelson D.R. Management of viral hepatitis in hematologic malignancies. Blood Rev. 2008; 22: 117–26.
  13. Luppi M., Longo G., Ferrari M.G. Clinico-pathological characterization of hepatitis C virus-related B-cell non-Hodgkin’s lymphomas without symptomatic cryoglobulinemia. Ann. Oncol. 1998; 9: 495–8.
  14. Mazzaro C., Tirelli U., Pozzato G. Hepatitis C virus and non-Hodgkin’s lymphoma 10 years later. Dig. Liver Dis. 2005; 37: 219–26.
  15. Arcaini L., Merli M., Volpetti S. et al. Indolent B-cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy. Clin. Dev. Immunol. 2012; 63: 81–5.
  16. Cervetti G., Mechelli S., Riccioni R. et al. High efficacy of Rituximab in indolent HCV-related lymphoproliferative disorders associated with systemic autoimmune diseases. Clin. Exp. Rheumatol. 2005; 23: 877–80.
  17. Nooka A., Shenoy P.J., Sinha R. et al. Hepatitis C reactivation in patients who have diffuse large B-cell lymphoma treated with rituximab: a case report and review of literature. Clin. Lymph. Myel. Leuk. 2011; 11: 379–84.
  18. Mahale P., Kontoyiannis D.P., Chemaly R.F. et al. Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients. J. Hepatol. 2012; 57: 1177–85.
  19. Coppola N., Pisaturo M., Guastafierro S. et al. Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with oncohaematological disease undergoing chemotherapy. Dig. Liver Dis. 2012; 44: 49–54.
  20. Torres H.A., Davila M. Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat. Rev. Clin. Oncol. 2012; 9: 156–66.
  21. Zuckerman E., Zuckerman T., Douer D. et al. Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematologic malignancies. Cancer 1998; 83: 1224–30.
  22. Ennishi D., Maeda Y., Niitsu N. et al. Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis. Blood 2010; 116: 5119–25.
  23. Nishikawa H., Tsudo M., Osaki Y. et al. Clinical outcome in diffuse large B-cell lymphoma with hepatitis C virus infection in the rituximab era: a single center experience. Oncol. Rep. 2012; 28: 835–40.
  24. Dizdar O., Tapan U., Aksoy S. et al. Liver dysfunction after chemotherapy in lymphoma patients infected with hepatitis C. Eur. J. Haematol. 2008; 80: 381–5.
  25. Silverman G.J., Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthr. Rheum. 2003; 48: 1484–92.
  26. Pitini V., Sturniolo G., Arrigo C. et al. HCV genotype 2 as a risk factor for reactivation in patients with B-cell lymphoma undergoing rituximab combination chemotherapy. Br. J. Haematol. 2010; 150: 116–8.
  27. Anoop P., Wotherspoon A., Matutes E. Severe liver dysfunction from hepatitis C virus reactivation following alemtuzumab treatment for chronic lymphocytic leukaemia. Br. J. Haematol. 2010; 148: 484–6.
  28. Floyd J., Mirza I., Sachs B., Perry M.C. Hepatotoxicity of chemotherapy. Semin. Oncol. 2006; 33: 50–67.
  29. Marotte H., Fontanges E., Bailly F. et al. Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus. Rheumatology (Oxford) 2007; 46: 97–9.
  30. Lin M.V., Blonski W., Buchner A.M. et al. The influence of anti-TNF therapy on the course of chronic hepatitis C virus infection in patients with inflammatory bowel disease. Dig. Dis. Sci. 2013; 58: 1149–56.
  31. Aslanidis S., Vassiliadis T., Pyrpasopoulou A. et al. Inhibition of TNFalpha does not induce viral reactivation in patients with chronic hepatitis C infection: two cases. Clin. Rheumatol. 2007; 26: 261–4.
  32. Watanabe T., Tanaka Y. Reactivation of hepatitis viruses following immunomodulating systemic chemotherapy. Hepatol. Res. 2013; 43: 113–21.
  33. Sagnelli E., Pisaturo M., Sagnelli C., Coppola N. Rituximab-based treatment, HCV replication, and hepatic flares. Clin. Dev. Immunol. 2012; 20: 945–50.
  34. Cano O., Almenar L., Martinez-Dolz L. et al. Course of patients with chronic hepatitis C virus infection undergoing heart transplantation. Transplant. Proc. 2007; 39: 2353–4.